Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » RNAssist Licenses Biomolecule Stabilization Tech to QCMD

RNAssist Licenses Biomolecule Stabilization Tech to QCMD

Jan 23, 2020
|
staff reporter

NEW YORK – UK-based technology development company RNAssist said this week that it has licensed its VivoPhix biomolecule stabilization technology to Quality Control for Molecular Diagnostics (QCMD).

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Same Old Error

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

Own Merits

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Back to Neanderthals

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

PNAS Papers on Small Molecule From Soil Bacteria, Circulating Tumor Cell Chip, More

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.

What's Popular?

In Business News

  1. Progenity Asks Court to Declare Non-Infringement of Natera Patents

  2. Cancer AI Startup Nucleai Raises $6.5M in Series A Financing

  3. Quidel Preliminary Q2 Revenues Jump More Than 86 Percent

  4. DiaSorin Molecular Gets CE Mark for Flu, RSV Assay

  5. Cancer Research UK, Abcam Partner to Develop Custom Antibodies for Cancer Research

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.